Compare PROP & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PROP | ENGN |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.6M | 99.8M |
| IPO Year | 2008 | N/A |
| Metric | PROP | ENGN |
|---|---|---|
| Price | $0.88 | $1.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $6.75 | ★ $21.08 |
| AVG Volume (30 Days) | ★ 3.2M | 3.2M |
| Earning Date | 05-15-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,939,000.00 | N/A |
| Revenue This Year | $81.83 | N/A |
| Revenue Next Year | $18.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $0.77 | $1.40 |
| 52 Week High | $4.33 | $12.25 |
| Indicator | PROP | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.81 | 27.48 |
| Support Level | N/A | $1.40 |
| Resistance Level | $1.93 | $9.16 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 22.74 | 4.61 |
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.